| Description | PA452 is a selective antagonist of retinoic X receptor (RXR) and suppresses the effect of Retinoic acid on Th1/Th2 development. |
| In vitro | PA452抑制了Troglitazone (TZ)诱导的CK13表达。在正常人类上皮细胞(NHU)中，PA452 (0.01-1 μM) 抑制维甲酸X受体[2]。 |
| molecular weight | 439.59 |
| Molecular formula | C26H37N3O3 |
| CAS | 457657-34-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: 4.4 mg/mL (10.01 mM), Sonication and heating are recommended. DMSO: 36 mg/mL (81.9 mM), Sonication is recommended. |
| References | 1. Iwata M, et al. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol. 2003 Aug;15(8):1017-25. 2. Varley CL, et al. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol. 2004 May;164(5):1789-98. |